Multiple Myeloma

Expert faculty review and share their insights and perspectives on key findings in multiple myeloma presented at the 2022 ASH Annual Meeting.

Share

Program Content

Activities

  • ASH 2022: Multiple Myeloma
    Key Studies in Multiple Myeloma: Independent Conference Coverage of ASH 2022
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 21, 2023

    Expires: March 20, 2025

Activities

DSMM XIII: Rd + ASCT + R vs Cont Rd
DSMM XIII: Phase III Trial of Rd Induction + ASCT With MEL140 Followed by R Maintenance vs Continuous Rd in Patients 60-75 Yr of Age With Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2022

Expires: December 11, 2023

Phase II GEM-CESAR
Phase II GEM-CESAR: Post Hoc Analyses of Sustained uMRD at 4 Yr After KRd + ASCT for High-Risk MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

MonumenTAL-1: Talquetamab
MonumenTAL-1: Phase I/II Study of GPCR5D x CD3 Bispecific Antibody Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

KarMMa-2 Cohort 2a
Phase II KarMMa-2 Cohort 2a: Idecabtagene Vicleucel in Patients With Multiple Myeloma With Early Relapse After Frontline ASCT
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

Mezigdomide + Dex in RR MM
Phase I/II Trial of Mezigdomide + Dexamethasone in R/R MM: Preliminary Results From the Dose-Expansion Phase II Cohort
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

IFM 2017-03: Dara + Len Without Dex
IFM 2017-03: Phase III Trial of Daratumumab + Lenalidomide vs Lenalidomide + Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

Myeloma XI: Len Maintenance
Myeloma XI: Exploring Optimal Duration of Lenalidomide Maintenance After ASCT From Phase III Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

ASCENT: Dara-KRd in SMM
ASCENT: Phase II Study of Fixed-Duration Therapy With Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone for High-Risk Smoldering MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

UK OPTIMUM/MUKnine: Dara-VRd in Ultra-High‒Risk NDMM
UK OPTIMUM/MUKnine: Phase II Trial of Intensified Dara-VRd Consolidation After ASCT in Ultra-High‒Risk Newly Diagnosed Multiple Myeloma and Primary Plasma Cell Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

Ide-Cel After BCMA-TT
Real-world Multicenter Retrospective Study of Idecabtagene Vicleucel in Patients With R/R MM After Previous BCMA-Targeted Therapy Exposure
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

Faculty

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen